Humacyte, Inc. HUMA 深 滬
等待開盤 02-05 09:30:00 美东时间
0.93
-0.069
-6.91%
華盛通- 最 高1.00
- 今 開0.9902
- 成交量 185.99万股
- 最 低 0.93
- 昨 收 0.999
- 總市值 1.48亿
- 52周最高 4.04
- 市盈率 靜 --
- 換手率 1.17%
- 52周最低 0.91
- 委 比 -54.44%
- 總股本 1.59亿
- 歷史最高 17.45
- 量 比 1.26
- 振 幅 7.01%
- 歷史最低 0.91
- 每 手 1
- 風險率 0.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
Benchmark Maintains Buy on Humacyte, Lowers Price Target to $10
Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $11 to $10.
01-21 23:36
Humacyte Plans To File MAA With Israel Ministry Of Health For Approval Of Acellular Tissue Engineered Vessel For Arterial Trauma Repair During Q1 2026
- Expansion plans are based on requests for product access received from surgeons and hospitals in Israel - - Expansion of Symvess into other territories, including those in Europe and the Middle East, is also
01-05 21:02
美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target
D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.
2025-12-22 22:59
Humacyte Terminates Revenue Interest And Option Agreements Dated May 12, 2023; Co To Pay Pay $38M Cash And Issue 5,725,190 Shares In Registered Offering
On December 15, 2025, the Humacyte, Inc. (the "Company") and Humacyte Global, Inc. ("Global") agreed with TPC Investments III LP and TPC Investments Solutions LP (collectively, the "Purchasers"), and Hook SA LLC, as
2025-12-15 22:18
Humacyte Terminates $80M Open Market Sale Agreement With Jefferies, Effective December 1; Company Is Not Subject To Any Termination Penalties Related To The Termination Of The Agreement
As previously disclosed, on September 1, 2022, Humacyte, Inc. (the "Company") entered into an Open Market Sale Agreement™ (the "Agreement") with Jefferies LLC ("Jefferies"), under which the Company may offer and
2025-11-27 06:14
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
2025-11-24 11:23
BTIG Reiterates Buy on Humacyte, Maintains $6 Price Target
BTIG analyst Ryan Zimmerman reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $6 price target.
2025-11-21 19:13
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
